<DOC>
	<DOCNO>NCT00215683</DOCNO>
	<brief_summary>This extension study study FE200486 CS12 ( NCT00819156 ) . Each participant treat discontinue withdrawn study , marketing authorization degarelix obtain . The study terminate ongoing participant treat least 5 year ( include one year main study ) .</brief_summary>
	<brief_title>An Extension Study Evaluating Long-Term Safety Tolerability Degarelix One-Month Depots Prostate Cancer</brief_title>
	<detailed_description>Participants complete main FE200486 CS12 study initially continue dose FE200486 CS12A extension study . After protocol amendment study participant treat 160 mg ( 40 mg/mL ) . The data include data participant participate main study ( FE200486 CS12 ; NCT00819156 ) extension study FE200486 CS12A .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Had give write consent studyrelated activity perform ( studyrelated activity define procedure would perform normal management participant ) Had complete FE200486 CS12 study Exclusion criterion : Had withdrawn FE200486 CS12 study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>